Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Deverra Therapeutics logo — Cell Therapies for All

Deverra Therapeutics

Cell Therapies for All

Founded 2020 United States Seattle, United States 14 employees Grant Total: $3.58M Biotechnology

General Information

Company Name Deverra Therapeutics
Founded Year 2020
Location United States Seattle, United States
Employees 14
Industries Biotechnology
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Deverra Therapeutics. To contact Deverra Therapeutics, visit deverratx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Deverra Therapeutics compare?

A PDF of Deverra Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Deverra Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Deverra Therapeutics

Deverra Therapeutics is a biotechnology startup founded in 2019 with a primary focus on developing allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company holds an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center, which is backed by over 20 years of federally funded research and data from 5 clinical trials. This cutting-edge platform enables the generation of a variety of unmodified and modified immune cells tailored for the treatment of cancer and infectious diseases. Deverra Therapeutics recently secured a $3.50 million grant investment from the Andy Hill Cancer Research Endowment (CARE) Fund on 11 September 2023. This funding injection is expected to bolster the company's research and development efforts in advancing its cell therapy technologies. With its innovative approach and strong backing from reputable institutions, Deverra Therapeutics is positioning itself as a key player in the biotechnology space, offering promising prospects for the future of cellular immunotherapies.

Business keywords: cell therapies, clinical stage, allogeneic cellular immunotherapies, stem cell expansion, directed differentiation platform, cancer treatment, infectious diseases treatment, proprietary technology, clinical trials, immunotherapy, Fred Hutchinson Cancer Research Center, immune cell therapy, therapeutic development, patient-centric treatment

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $3.50M 1
Andy Hill Cancer Research Endowment (CARE) Fund
Andy Hill Cancer Research Endowment (CARE) Fund
11 Sep 2023
Pre Seed Round $75.00K -
20 Aug 2020

Deverra Therapeutics Alternatives & Competitors

View All Alternatives
Deverra Therapeutics vs
Celularity Inc.
Celularity Inc. United States

A next-gen Biotech company creating off-the-shelf cellular medicines for Cancer, Infectious, and Deg...

Post-IPO Equity
171 employees
Biotechnology, Health Care
Deverra Therapeutics vs
AlloVir
AlloVir United States

A global leader in allogeneic, off-the-shelf, multi-virus specific T- cell immunotherapies

Post-IPO Equity
32 employees
Biotechnology, Pharmaceutical
Deverra Therapeutics vs
SQZ Biotechnologies
SQZ Biotechnologies United States

Unlocking the full potential of cell therapies for patients around the world

Grant
18 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Deverra Therapeutics

Cell Therapies for All
Deverra Therapeutics was founded in 2020.
Deverra Therapeutics is headquartered in Seattle, United States.
Deverra Therapeutics operates in Biotechnology. Its work centres on cell therapies, clinical stage, allogeneic cellular immunotherapies and stem cell expansion.
Deverra Therapeutics has approximately 14 employees.
Deverra Therapeutics has completed 2 funding rounds, raising a total of $3.58M. The latest funding stage is Grant.
Top alternatives and competitors to Deverra Therapeutics include Celularity Inc., AlloVir, SQZ Biotechnologies, Cartesian Therapeutics, Progenitor Life Sciences, LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Deverra Therapeutics and Celularity Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Deverra Therapeutics, https://bouncewatch.com/company/deverra-therapeutics, updated 11 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout